Management Team
Artem Zykovich, PhD
Co-Founder and Chief Executive Officer
​
Dr. Zykovich was a Co-Founder and VP of Research and Development at AltiBio Inc. He oversaw pre-clinical studies and was the primary inventor of two patent applications. Prior to AltiBio, Dr. Zykovich was the scientist at Raptor Pharmaceuticals who led genetic testing initiatives for market expansion of PROCYSBI®. Dr. Zykovich served as a scientist at the Buck Institute for Research on Aging. Dr. Zykovich earned an MS in Biology & Genetics from Novosibirsk State University and a Ph.D. in Pharmacology & Toxicology from the University of California, Davis.
Wolfgang Richter, PhD
Head of CMC
​
Dr. Richter has more than 25 years of experience in the biotech industry as a founder and in different key management positions of several life science companies, including Morphochem AG, R&D-Biopharmaceuticals GmbH, and TUBE Pharmaceuticals GmbH. His areas of expertise are CMC, preclinical and formulation development, IP management, in- and out-licensing. Dr. Richter is an inventor or co-inventor of more than a dozen of patents.
Kim R. Tsuchimoto
Acting Chief Financial Officer
​
Ms. Tsuchimoto also severs as Chief Financial Officer at Monopar Therapeutics, where she oversaw the initial public offering on Nasdaq. Ms. Tsuchimoto has spent over nine years at Raptor Pharmaceuticals, as its Chief Financial Officer, where she completed: two reverse mergers, one to initially trade on the OTCBB, the second to gain Raptor’s Nasdaq listing; over $100 million of financings (primarily equity). Prior to Raptor, Ms. Tsuchimoto spent eight years at BioMarin Pharmaceutical where she held the positions of Vice President-Treasurer, Vice President-Controller, and Controller. At BioMarin, Ms. Tsuchimoto provided due diligence for the company’s IPO and helped close BioMarin’s first $500 million of financing. Ms. Tsuchimoto received a B.S. in Business Administration from San Francisco State University.
Board of Directors
Erich Sager, MBA
Co-Founder, Chairman
​
Mr. Sager previously served as the Chairman of the Board of Raptor Pharmaceuticals. Raptor raised $200M in the public market, developed and commercialized PROCYSBI, and was sold to Horizon Therapeutics for $800M. Mr. Sager served on the board of directors of BioMarin and as chairman of LaMont Asset Management SA, a private investment management firm. Mr. Sager serves as the Chairman of the Board of Mercaptor Discoveries. Mr. Sager also serves on the boards of several companies, including Limetree Capital SA, Holding TwentyOne AG, Calltrade Carrier Services AG. Mr. Sager received an undergraduate degree and an MBA from the School of Economics and Business Administration in Zurich, Switzerland.
Artem Zykovich, PhD
Co-Founder and Chief Executive Officer
​
Advisors
Larry Greenbaum, MD, PhD
​
Dr. Greenbaum is Division Director of Pediatric Nephrology and the Bernard Marcus Professor of Pediatric Nephrology at the Emory School of Medicine in Atlanta. He is also the Director of Pediatric Nephrology at Children’s Healthcare of Atlanta. He received his MD and PhD degrees from the Yale School of Medicine and completed a residency in Pediatrics and a fellowship in Pediatric Nephrology at the UCLA School of Medicine. Dr. Greenbaum conducts clinical research in a variety of areas in pediatric nephrology, including kidney osteodystrophy, cystinosis, chronic kidney disease, and nephrotic syndrome. He co-edited the textbooks Practical Strategies in Pediatric Diagnosis and Therapy and Clinical Pediatric Nephrology. He is a major contributor to Nelson Textbook of Pediatrics. He has received multiple awards for teaching residents and medical students. Dr. Greenbaum has served as President of the American Society of Pediatric Nephrology and as the chair of the Executive Committee of the American Academy of Pediatrics Section on Nephrology. He is currently on the steering committee of the Pediatric Nephrology Research Consortium.
Along with conducting research in cystinosis, Dr. Greenbaum has been on the Medical Advisory Committee of the Cystinosis Research Network (patient advocacy organization) for more than a decade and also serves on the Medical and Scientific Advisory Board and the Scientific Review Board of the Cystinosis Research Foundation (patient advocacy organization). He enjoys caring for patients with cystinosis and sees children and adults with cystinosis from throughout the United States.
Ted Daley
​
Mr. Daley is co-founder and CEO of Selva Therapeutics, a clinical-stage biotech company focused on infectious diseases. Previously Ted was President and Chief Business Officer of Raptor Pharmaceuticals, a publicly-traded biotech focused on rare diseases. At Raptor Ted was responsible for the development and US and Europe regulatory approval of PROCYSBI, the first new treatment for cystinosis in over 20 years. Before that Ted was founder and CEO of Convivia, Inc., a seed-stage biotech that was acquired by Raptor.